Loading...

Primary Tumor Response to Targeted Agents in Patients with Metastatic Renal Cell Carcinoma

BACKGROUND: The recent development of multiple targeted agents for metastatic renal cell carcinoma (mRCC) has changed the treatment paradigm; hence the benefit and optimal timing of cytoreductive nephrectomy is being reevaluated. OBJECTIVE: To determine primary tumor response to treatment with targe...

Full description

Saved in:
Bibliographic Details
Published in:Eur Urol
Main Authors: Abel, E. Jason, Culp, Stephen H., Tannir, Nizar M., Matin, Surena F., Tamboli, Pheroze, Jonasch, Eric, Wood, Christopher G.
Format: Artigo
Language:Inglês
Published: 2010
Subjects:
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC4378833/
https://ncbi.nlm.nih.gov/pubmed/20952123
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.eururo.2010.09.034
Tags: Add Tag
No Tags, Be the first to tag this record!